RXRX · Recursion Pharmaceuticals, Inc.

Summary

Recursion Pharmaceuticals, Inc. announced on March 25, 2026, that Vicki Goodman, M.D., will become Chief Medical Officer effective April 6, 2026, succeeding David Mauro, M.D., Ph.D., who will transition out of the role and serve in an advisory capacity until May 29, 2026. This change supports advancing the clinical pipeline toward key milestones.

Key takeaways

• Vicki Goodman, M.D., appointed Chief Medical Officer effective 2026-04-06
• David Mauro, M.D., Ph.D., departing Chief Medical Officer role
• David Mauro to serve in advisory capacity until 2026-05-29
• Goodman previously Chief Medical Officer at Mural Oncology and Executive Vice President at Exelixis
• Mauro contributed to clinical portfolio including REC-4881 progression